NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $3.28 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.72 +0.44 (+13.54%) As of 05/22/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDRX alerts:Sign Up Key Stats Today's Range$3.13▼$3.3050-Day Range$3.06▼$4.8652-Week Range$2.86▼$66.50Volume19,931 shsAverage Volume980,105 shsMarket Capitalization$6.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom. Read More Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreBDRX MarketRank™: Biodexa Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.86% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 58.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for BDRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by Institutions17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDRX Stock News HeadlinesBiodexa issues letter to ShareholdersMay 14, 2026 | globenewswire.comBiodexa Pharmaceuticals PLC - Depositary receipt (BDRX) price target decreased by 80.56% to 35.70April 9, 2026 | msn.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 25 at 1:00 AM | Brownstone Research (Ad)Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesApril 2, 2026 | globenewswire.comTanner Pharma Group and Biodexa Launch Global Early Access Program for FAP PatientsMarch 31, 2026 | finance.yahoo.comBDRX: Initiating coverage of Biodexa Pharmaceuticals; a deep value oncology platform built around two high-conviction areasMarch 30, 2026 | msn.comPreliminary Results for the Year Ended 31 December 2025March 27, 2026 | globenewswire.comBiodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma GroupMarch 23, 2026 | globenewswire.comSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $11.35 at the start of the year. Since then, BDRX stock has decreased by 71.1% and is now trading at $3.28. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) announced its earnings results on Friday, March, 27th. The company reported $3.53 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $3.53. When did Biodexa Pharmaceuticals' stock split? Shares of Biodexa Pharmaceuticals reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, March 18th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include SoundHound AI (SOUN), Dyne Therapeutics (DYN), NVIDIA (NVDA), Viking Therapeutics (VKTX), TRACON Pharmaceuticals (TCON), ASE Technology (ASX) and BigBear.ai (BBAI). Company Calendar Last Earnings3/27/2026Today5/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BDRX's financial health is in the Yellow zone, according to TradeSmith. BDRX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDRX Previous SymbolLON:MTPH CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual Sales$470 thousand Price / Sales13.96 Cash FlowN/A Price / Cash FlowN/A Book Value$110.30 per share Price / Book0.03Miscellaneous Outstanding Shares2,000,000Free Float1,989,000Market Cap$6.56 million OptionableNot Optionable Beta1.15 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BDRX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
